Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, Messina JL, Smalley KSM.

Semin Cancer Biol. 2019 Nov 2. pii: S1044-579X(19)30343-8. doi: 10.1016/j.semcancer.2019.10.017. [Epub ahead of print] Review.

PMID:
31689494
2.

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, Sondak VK, Messina JL, Babacan NA, Maria-Engler SS, De Armas L, Williams SL, Gatenby RA, Chen YA, Anderson ARA, Smalley KSM.

EBioMedicine. 2019 Oct;48:178-190. doi: 10.1016/j.ebiom.2019.09.023. Epub 2019 Oct 5.

3.

Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG.

Cancer Immunol Res. 2019 Nov;7(11):1755-1759. doi: 10.1158/2326-6066.CIR-18-0717. Epub 2019 Aug 28.

PMID:
31462410
4.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.

Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS.

Clin Cancer Res. 2019 Oct 1;25(19):5961-5971. doi: 10.1158/1078-0432.CCR-18-4159. Epub 2019 Aug 9.

PMID:
31399473
5.

Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma.

Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J.

Pigment Cell Melanoma Res. 2019 Jul 22. doi: 10.1111/pcmr.12813. [Epub ahead of print]

PMID:
31329344
6.

Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.

Broman KK, Dossett LA, Sun J, Eroglu Z, Zager JS.

Expert Opin Drug Saf. 2019 May;18(5):381-392. doi: 10.1080/14740338.2019.1607289. Epub 2019 Apr 24. Review.

PMID:
30977681
7.

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB.

J Immunother. 2019 Jul/Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.

PMID:
30882548
8.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3.

PMID:
30767428
9.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
10.

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.

Sun J, Zager JS, Eroglu Z.

Onco Targets Ther. 2018 Dec 14;11:9081-9089. doi: 10.2147/OTT.S171693. eCollection 2018. Review.

11.

Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma.

Eroglu Z, Ozgun A.

Expert Opin Orphan Drugs. 2018;6(9):545-551. doi: 10.1080/21678707.2018.1512402. Epub 2018 Aug 28.

12.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

13.

Effect of topical ozonetherapy on gingival wound healing in pigs: histological and immuno-histochemical analysis.

Eroglu ZT, Kurtis B, Altug HA, Sahin S, Tuter G, Baris E.

J Appl Oral Sci. 2018 Dec 10;27:e20180015. doi: 10.1590/1678-7757-2018-0015.

14.

The relationship of the endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) gene polymorphism in Turkish type 2 diabetic patients with and without diabetic foot ulcers.

Erdogan M, Kulaksizoglu M, Tetik A, Solmaz S, Kucukaslan AS, Eroglu Z.

Foot (Edinb). 2018 Dec;37:5-10. doi: 10.1016/j.foot.2018.06.006. Epub 2018 Jun 26.

PMID:
30321858
15.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

16.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

17.

Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia.

Eroğlu Z, Tetik Vardarlı A, Düzgün Z, Gündüz C, Bozok Çetintaş V, Kayıkçıoğlu M.

Anatol J Cardiol. 2018 May;19(5):334-340. doi: 10.14744/AnatolJCardiol.2018.86648.

18.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.

Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM.

Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19.

PMID:
29674508
19.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA.

Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.

20.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

21.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM.

Mol Cancer Ther. 2018 Jan;17(1):73-83. doi: 10.1158/1535-7163.MCT-17-0196. Epub 2017 Nov 13.

22.

Matrine induced G0/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells.

Tetik Vardarlı A, Düzgün Z, Erdem C, Kaymaz BT, Eroglu Z, Çetintas VB.

Bosn J Basic Med Sci. 2018 May 20;18(2):141-149. doi: 10.17305/bjbms.2017.2457.

23.

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.

Ann Oncol. 2018 Jan 1;29(1):250-255. doi: 10.1093/annonc/mdx642.

24.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT.

J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.

PMID:
28991513
25.

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia.

Kaya E, Kayıkçıoğlu M, Tetik Vardarlı A, Eroğlu Z, Payzın S, Can L.

Anatol J Cardiol. 2017 Oct;18(4):266-272. doi: 10.14744/AnatolJCardiol.2017.7654. Epub 2017 Aug 2.

26.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

27.

Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia.

Tetik Vardarlı A, Harman E, Bozok Çetintaş V, Kayıkçıoğlu M, Vardarlı E, Zengi A, Küçükaslan AŞ, Eroğlu Z.

Anatol J Cardiol. 2017 Apr;17(4):313-321. doi: 10.14744/AnatolJCardiol.2016.7142. Epub 2017 Mar 3.

28.

Improving clinical outcomes with pembrolizumab in patients with advanced melanoma.

Kim DW, Zager JS, Eroglu Z.

Chin Clin Oncol. 2017 Feb;6(1):2. doi: 10.21037/cco.2017.01.04. No abstract available.

29.

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.

Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D.

J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.

30.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
31.

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.

Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS.

J Immunother Cancer. 2016 Dec 20;4:85. doi: 10.1186/s40425-016-0194-1. eCollection 2016.

32.

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB.

J Immunother Cancer. 2016 Oct 18;4:60. eCollection 2016.

33.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.

34.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

35.

LDLR C1725T Gene Polymorphism Frequency in Type 2 Diabetes Mellitus Patients With Dyslipidemia.

Eroglu Z, Harman E, Vardarli E, Kayikcioglu M, Vardarli AT.

J Clin Med Res. 2016 Nov;8(11):793-796. Epub 2016 Sep 29.

36.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.

Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443.

PMID:
27687304
37.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
38.

Improving patient outcomes to targeted therapies in melanoma.

Eroglu Z, Smalley KS, Sondak VK.

Expert Rev Anticancer Ther. 2016 Jun;16(6):633-41. doi: 10.1080/14737140.2016.1178575. Epub 2016 May 12. Review.

PMID:
27137746
39.

Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum.

Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE.

Pigment Cell Melanoma Res. 2016 Jul;29(4):470-3. doi: 10.1111/pcmr.12482. No abstract available.

40.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

41.

Combination Therapies for Melanoma: A New Standard of Care?

Smalley KS, Eroglu Z, Sondak VK.

Am J Clin Dermatol. 2016 Apr;17(2):99-105. doi: 10.1007/s40257-016-0174-8. Review.

42.

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.

Eroglu Z, Ribas A.

Ther Adv Med Oncol. 2016 Jan;8(1):48-56. doi: 10.1177/1758834015616934. Review.

43.

Sequencing of mutations in the serine/threonine kinase domain of the bone morphogenetic protein receptor type 2 gene causing pulmonary arterial hypertension.

Mutlu Z, Kayıkçıoğlu M, Nalbantgil S, Vuran Ö, Kemal H, Moğulkoç N, Ertürk B, Onay H, Eroğlu Z, Kültürsay H.

Anatol J Cardiol. 2016 Jul;16(7):491-496. doi: 10.5152/AnatolJCardiol.2015.6297. Epub 2015 Sep 15.

44.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

45.

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A.

Eur J Cancer. 2015 Nov;51(17):2689-97. doi: 10.1016/j.ejca.2015.08.012. Epub 2015 Sep 10.

46.

Role of mTOR in glioblastoma.

Duzgun Z, Eroglu Z, Biray Avci C.

Gene. 2016 Jan 10;575(2 Pt 1):187-90. doi: 10.1016/j.gene.2015.08.060. Epub 2015 Sep 1. Review.

PMID:
26341051
47.

miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells.

Bozok Çetintaş V, Tetik Vardarlı A, Düzgün Z, Tezcanlı Kaymaz B, Açıkgöz E, Aktuğ H, Kosova Can B, Gündüz C, Eroğlu Z.

Tumour Biol. 2016 Feb;37(2):1739-51. doi: 10.1007/s13277-015-3950-9. Epub 2015 Aug 28.

PMID:
26314859
48.

An Association Study Between Gene Polymorphisms of Folic Acid Metabolism Enzymes and Biochemical and Hormonal Parameters in Acromegaly.

Tetik Vardarlı A, Zengi A, Bozok Çetintaş V, Karadeniz M, Tamsel S, Küçükaslan AŞ, Köse T, Saygılı F, Eroglu Z.

Genet Test Mol Biomarkers. 2015 Aug;19(8):431-8. doi: 10.1089/gtmb.2015.0076. Epub 2015 Jul 8.

PMID:
26154858
49.

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.

Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA.

Br J Cancer. 2015 May 12;112(10):1644-51. doi: 10.1038/bjc.2015.126. Epub 2015 Apr 21.

50.

Steady, dynamic, creep/recovery, and textural properties of yoghurt/molasses blends: Temperature sweep tests and applicability of Cox-Merz rule.

Eroglu A, Bayrambaş K, Eroglu Z, Toker OS, Yilmaz MT, Karaman S, Dogan M.

Food Sci Technol Int. 2016 Jan;22(1):31-46. doi: 10.1177/1082013214566478. Epub 2015 Jan 22.

PMID:
25614154

Supplemental Content

Loading ...
Support Center